Regis Technologies
Alan Henderson has extensive work experience in the pharmaceutical industry. Alan currently serves as the Vice President of Chemistry at Regis Technologies. Prior to this role, they held various positions at Curia (formerly AMRI), including Director of Business Excellence & Development Support, Director of Chemical Development, Director of Chemistry, Assistant Director of Chemistry, and Section Head of Chemistry. In these roles, they oversaw various aspects of insourcing collaborations with companies such as Eli Lilly, managing teams of chemists and supporting activities in medicinal chemistry, chemical development, process chemistry, and manufacturing. Before joining Curia, Henderson worked as a Senior Scientist at Pfizer.
Alan Henderson attended The University of Edinburgh from 1992 to 1995, where they earned a BSc (Hons) degree in Chemistry. Following this, they pursued further education at the University of Cambridge from 1995 to 1999, completing a Ph.D. in Organic Chemistry.
Regis Technologies
Regis Technologies, Inc. partners with pharmaceutical and biotechnology companies to help advance drug candidates to market. Our services streamline and support your discovery, lead molecule development and drug commercialization – from process development and analytical development, to stability services and cGMP API manufacturing. Our facilities are routinely inspected by the FDA and other global regulatory authorities. With our extensive organic chemistry & separations expertise, Regis also manufactures an innovative line of proprietary chromatography products sold throughout the world. Regis is privately owned and operated and has been in business in the Chicagoland area since 1956.